Mutations in TP53 and DNA damage repair genes have a negative impact on the response to first-line systemic therapy in men with prostate cancer

被引：0

作者：

Nientiedt, C. ^{[1
,2
]}

Wuenschel, A. -K ^{[3
]}

Kaczorowski, A. ^{[3
]}

Endris, V ^{[4
]}

Zschaebitz, S. ^{[1
]}

Jaeger, D. ^{[1
]}

Hohenfellner, M. ^{[5
]}

Stenzinger, A.

Duensing, S. ^{[3
]}

机构：

[1] NCT Natl Ctr Tumorerkrankungen Heidelberg, Med Onkol, Heidelberg, Germany

[2] Klin Innere Med Hamatol Onkol & Stammzelltranspla, Freiburg, Germany

[3] Urol Clin, Mol Uroonkol, Heidelberg, Germany

[4] Pathol Inst, Allgemeine Pathol, Heidelberg, Germany

[5] Urol Clin, Heidelberg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V836

引用

页码：112 / 112

页数：1

共 50 条

[41] NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment [J].

Chiaretti, Sabina ;

Marinelli, Marilisa ;

Del Giudice, Ilaria ;

Bonina, Silvia ;

Piciocchi, Alfonso ;

Messina, Monica ;

Vignetti, Marco ;

Rossi, Davide ;

Di Maio, Valeria ;

Mauro, Francesca Romana ;

Guarini, Anna ;

Gaidano, Gianluca ;

Foa, Robin .

LEUKEMIA & LYMPHOMA, 2014, 55 (12) :2785-2792

[42] Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer [J].

Berchuck, Jacob E. ;

Zhang, Zhenwei ;

Silver, Rebecca ;

Kwak, Lucia ;

Xie, Wanling ;

Lee, Gwo-Shu Mary ;

Freedman, Matthew L. ;

Kibel, Adam S. ;

Van Allen, Eliezer M. ;

McKay, Rana R. ;

Taplin, Mary-Ellen .

EUROPEAN UROLOGY, 2021, 80 (03) :295-303

[43] Effect of concurrent TP53 mutation in EGFR/ALK/ROS1 positive non-small cell lung cancer treated with first-line TKI therapy: A Single Institution Retrospective Study. [J].

Sharma, Sandhya ;

Miao, Emily ;

Fishbein, Joanna Stein ;

Lee, Chung-Shien ;

Sullivan, Kevin M. ;

Seetharamu, Nagashree .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[44] TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration- resistant prostate cancer (mCRPC)-First interim analysis (IA) [J].

De Bono, Johann S. ;

Mehra, Niven ;

Higano, Celestia S. ;

Saad, Fred ;

Buttigliero, Consuelo ;

Mata, Marielena ;

Chen, Hsiang-Chun ;

Healy, Cynthia G. ;

Paccagnella, M. Luisa ;

Czibere, Akos ;

Fizazi, Karim .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)

[45] Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study [J].

Koh, Su-Jin ;

Ohsumi, Shozo ;

Takahashi, Masato ;

Fukuma, Eisuke ;

Jung, Kyung Hae ;

Ishida, Takanori ;

Dai, Ming-Shen ;

Chang, Chuan-Hsun ;

Dalvi, Tapashi ;

Walker, Graham ;

Bennett, James ;

O'Shaughnessy, Joyce ;

Balmana, Judith .

BREAST CANCER, 2022, 29 (01) :92-102

[46] Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study [J].

Su-Jin Koh ;

Shozo Ohsumi ;

Masato Takahashi ;

Eisuke Fukuma ;

Kyung Hae Jung ;

Takanori Ishida ;

Ming-Shen Dai ;

Chuan-Hsun Chang ;

Tapashi Dalvi ;

Graham Walker ;

James Bennett ;

Joyce O’Shaughnessy ;

Judith Balmaña .

Breast Cancer, 2022, 29 :189-190

[47] Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients [J].

Liu, Binliang ;

Yi, Zongbi ;

Guan, Yanfang ;

Ouyang, Quchang ;

Li, Chunxiao ;

Guan, Xiuwen ;

Lv, Dan ;

Li, Lixi ;

Zhai, Jingtong ;

Qian, Haili ;

Xu, Binghe ;

Ma, Fei ;

Zeng, Yixin .

CANCER MEDICINE, 2022, 11 (14) :2767-2778

[48] The impact of TP53 mutations on EGFR mt plus NSCLC IV patients treated with 3rd generation TKI on 2nd line or further line therapy: Real-world data from two certified lung cancer centers in Germany [J].

Roeper, J. ;

Christopoulos, P. ;

Falk, M. ;

Heukamp, L. C. ;

Stenzinger, A. ;

Thomas, M. ;

Griesinger, F. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) :S772-S773

[49] Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database [J].

Parikh, Kaushal ;

Dimou, Anastasios ;

Leventakos, Konstantinos ;

Mansfield, Aaron S. ;

Shanshal, Mohamed ;

Wan, Yin ;

Lin, Huamao M. ;

Vincent, Sylvie ;

Elliott, Jennifer ;

Bonta, Ioana R. .

JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (11) :1539-1549

[50] Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review [J].

Xu, Tianyuan ;

Guo, Hanxu ;

Xie, Jun ;

He, Yanyan ;

Che, Jianping ;

Peng, Bo ;

Yang, Bin ;

Yao, Xudong .

FRONTIERS IN ONCOLOGY, 2023, 13

← 1 2 3 4 5 →